Author

S. A. Grupp

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:genetic perturbation / CRISPR· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:CITE-seq· 1

Frequent Co-Authors

C. H. June· 2 shared D. M. Barrett· 2 shared S. L. Berger· 2 shared A. Chandra· 1 shared A. E. Baxter· 1 shared A. J. Dimitri· 1 shared B. L. Levine· 1 shared C. Burudpakdee· 1 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

C. H. June

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

TET2 regulates early and late transitions in exhausted CD8+ T-cell differentiation and limits CAR T-cell function

A. J. Dimitri, A. E. Baxter, G. M. Chen, C. R. Hopkins, G. T. Rouin, H. Huang, W. Kong, C. H. Holliday, V. Wiebking, R. Bartoszek, S. Drury, K. Dalton, O. M. Koucky, Z. Chen, J. R. Giles, , J. A. Fraietta

This study shows that targeting TET2 in CAR T-cells improves their anti-tumor responses by limiting terminal exhaustion and enhancing therapeutic potential.

bioRxiv · Mar 29, 2024Immunology

Distinct bioenergetic features of human invariant natural killer T (iNKT) cells enable retained functions in nutrient-deprived states

P. Khurana, C. Burudpakdee, S. A. Grupp, U. H. Beier, D. M. Barrett, H. Bassiri

This study identifies distinct bioenergetic features of human iNKT cells that enable their survival and effector function in nutrient-deprived conditions compared to conventional T cells.

bioRxiv · Apr 29, 2021Immunology

Single-cell antigen-specific activation landscape of CAR T infusion product identifies determinants of CD19 positive relapse in patients with ALL

Z. Bai, S. Woodhouse, D. Kim, S. Lundh, H. Sun, Y. Deng, Y. Xiao, D. M. Barrett, R. M. Myers, S. A. Grupp, C. H. June, J. J. J. Joseph Melenhorst, P. G. Camara, R. Fan

The paper analyzes single-cell data from CAR T infusion products to identify factors associated with CD19-positive relapse in ALL patients.

bioRxiv · Apr 15, 2021Immunology

Impaired tumor death receptor signaling drives resistance to CAR T cell therapy

N. Singh, O. Shestova, P. Ravikumar, K. Hayer, S. J. Hong, E. J. Orlando, K. T. Mueller, C. R. Good, S. L. Berger, O. Shalem, M. D. Weitzman, S. A. Grupp, C. H. June, S. Gill, M. Ruella

This study identifies impaired death receptor signaling as a driver of resistance to CAR T cell therapy in B-cell leukemia by showing its role in tumor survival and T cell dysfunction.

bioRxiv · May 5, 2019 · PreprintImmunology